Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Addgene is open for ordering and depositing; find up-to-date details here. To learn more about how we are supporting COVID-19 research and to find related plasmids, check out our COVID-19 and Coronavirus Plasmids & Resources page.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected] Learn more

lenti-sgRNA blast
(Plasmid #104993)


Item Catalog # Description Quantity Price (USD)
Plasmid 104993 Standard format: Plasmid sent in bacteria as agar stab 1 $75

This material is available to academics and nonprofits only.


  • Vector backbone
    lentiCRISPRv2 blast (Addgene #98293)
  • Backbone manufacturer
    Brett Stringer from Feng Zhang plasmid lentiCRISPR v2 (Addgene plasmid #52961)
  • Backbone size (bp) 10437
  • Modifications to backbone
    The first of the two MluI restriction sites of lentiCRISPR v2 (Addgene plasmid #52961) was mutated (to create lentiCRISPRv2 puro, Addgene plasmid #98290) to allow the subcloning of alternative P2A-antibiotic resistance cassettes between the BamHI and remaining MluI restriction site (see lentiCRISPRv2 hygro, Addgene plasmid #98291; lentiCRISPRv2 neo, Addgene plasmid #98292; and lentiCRISPRv2 blast, Addgene plasmid #98293). The Cas9-P2A-blast cassette of lentiCRISPRv2 blast (Addgene plasmid #98293) was removed by XbaI/MluI digestion and the blasticidin resistance gene sequence was cloned in its place between the XbaI and MluI restriction sites downstream of the EF-1alpha core promoter (see also lentiGuide puro, Addgene plasmid #104990; lentiGuide hygo, Addgene plasmid #104991; and lentiGuide neo, Addgene plasmid #104992).
  • Vector type
    Mammalian Expression, Lentiviral, CRISPR
  • Selectable markers

Growth in Bacteria

  • Bacterial Resistance(s)
  • Growth Temperature
  • Growth Strain(s)
  • Growth instructions
    Single colonies of transformed STBL3 or STBL4 cells cultured in 5 ml of LB broth containing 100 micrograms/ml ampicillin for 20 hours at 37C, 200 rpm give good yields for plasmid minipreps.
  • Copy number
    High Copy

Resource Information

  • Supplemental Documents
  • A portion of this plasmid was derived from a plasmid made by
    The blasticidin resistance gene sequence was amplified by PCR from pcDNA™6/TR (Invitrogen)
  • Terms and Licenses
  • Industry Terms
    • Not Available to Industry

Depositor Comments

This 3rd generation lentiviral plasmid expresses a S. pyogenes CRISPR chimeric RNA element with a customizable sgRNA from a U6 promoter and blasticidin resistance gene from an EF-1a core promoter.
This plasmid does NOT contain Cas9. It should be used in conjunction with lentiCas9 puro, lentiCas9 hygro or lentiCas9 neo or with cell lines expressing Cas9.
After cloning a double-stranded oligonucleotide specifying a gRNA between the two BsmBI restriction sites, use hU6-F (5'-GAGGGCCTATTTCCCATGATT-3') or LKO.1 5’(5'- GACTATCATATGCTTACCGT-3') to sequence the chimeric RNA element.
Instruction for gRNA double-stranded oligonucleotide design and cloning can be found in the Zhang lab protocol,

How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    lenti-sgRNA blast was a gift from Brett Stringer (Addgene plasmid # 104993 ; ; RRID:Addgene_104993)
  • For your References section:

    A reference collection of patient-derived cell line and xenograft models of proneural, classical and mesenchymal glioblastoma. Stringer BW, Day BW, D'Souza RCJ, Jamieson PR, Ensbey KS, Bruce ZC, Lim YC, Goasdoue K, Offenhauser C, Akgul S, Allan S, Robertson T, Lucas P, Tollesson G, Campbell S, Winter C, Do H, Dobrovic A, Inglis PL, Jeffree RL, Johns TG, Boyd AW. Sci Rep. 2019 Mar 20;9(1):4902. doi: 10.1038/s41598-019-41277-z. 10.1038/s41598-019-41277-z PubMed 30894629